



## Clinical trial results:

**A multicentre, randomized, double-blind, parallel-group, controlled study, to assess the efficacy and safety of P-3074 cutaneous spray, solution, in the treatment of male pattern baldness.**

### Summary

EudraCT number	2015-002877-40
Trial protocol	DE HU BE ES
Global end of trial date	05 March 2018

### Results information

Result version number	v1
This version publication date	15 March 2019
First version publication date	15 March 2019

### Trial information

#### Trial identification

Sponsor protocol code	PM1541
-----------------------	--------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03004469
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Polichem S.A.
Sponsor organisation address	50, Val Fleuri Luxembourg, legally represented by branch in, Lugano-Pazzallo, Switzerland, CH-6912
Public contact	Francesco Scarci, Polichem S.A., +41 091 9864 005, francesco.scarci@almirall.com
Scientific contact	Francesco Scarci, Polichem S.A., +41 091 9864 005, francesco.scarci@almirall.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 November 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	05 March 2018
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To determine whether a daily treatment with P-3074 for 24 weeks increases hair count in men with male pattern baldness (MPB) compared to the vehicle.

Protection of trial subjects:

The study was conducted under the provisions of the Declaration of Helsinki, and in accordance with the International Conference on Harmonization (ICH) Consolidated Guideline on Good Clinical Practice (GCP).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 August 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 37
Country: Number of subjects enrolled	Belgium: 13
Country: Number of subjects enrolled	Germany: 286
Country: Number of subjects enrolled	Hungary: 38
Country: Number of subjects enrolled	Russian Federation: 84
Worldwide total number of subjects	458
EEA total number of subjects	374

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	458

From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted in 5 countries, in 52 sites and was initiated on 02 Aug 2016 (First subject first visit) and the study got completed on 05 Mar 2018 (Last subject last visit).

### Pre-assignment

Screening details:

A total of 632 subjects were screened, with 458 subjects being randomized.

### Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	P-3074 + Finasteride Placebo

Arm description:

Subjects received topical application of P-3074 contained finasteride 0.25% in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.

Arm type	Experimental
Investigational medicinal product name	P-3074
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cutaneous spray, solution
Routes of administration	Topical use

Dosage and administration details:

Subjects received topical application of P-3074 contained finasteride 0.25% in morning onto dry scalp only (up to 4 puffs) for 24 weeks.

Investigational medicinal product name	Finasteride Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo of finasteride 1-milligram (mg) tablet orally once daily for 24 weeks.

<b>Arm title</b>	P-3074 Vehicle + Finasteride Placebo
------------------	--------------------------------------

Arm description:

Subjects received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.

Arm type	Placebo
Investigational medicinal product name	P-3074 Vehicle
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cutaneous spray, solution
Routes of administration	Cutaneous use

Dosage and administration details:

Subjects received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for 24 weeks.

Investigational medicinal product name	Finasteride Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subject received placebo of finasteride 1 mg tablet orally once daily for 24 weeks	
<b>Arm title</b>	Oral Finasteride + P-3074 Vehicle

Arm description:

Subjects received finasteride 1 mg tablet orally once daily followed by topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for the 24 weeks.

Arm type	Active comparator
Investigational medicinal product name	Finasteride
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received finasteride 1 mg tablet orally once daily for 24 weeks.

Investigational medicinal product name	P-3074 Vehicle
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cutaneous spray, solution
Routes of administration	Cutaneous use

Dosage and administration details:

Subject received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for 24 weeks.

<b>Number of subjects in period 1</b>	<b>P-3074 + Finasteride Placebo</b>	<b>P-3074 Vehicle + Finasteride Placebo</b>	<b>Oral Finasteride + P- 3074 Vehicle</b>
Started	189	184	85
Completed	128	135	60
Not completed	61	49	25
Consent withdrawn by subject	29	27	10
Non-Compliance with Study Drug	2	-	-
Adverse event, non-fatal	6	4	6
Protocol violation	-	-	1
Unspecified reason	-	4	1
Lost to follow-up	23	14	6
Lack of efficacy	1	-	1

## Baseline characteristics

### Reporting groups

Reporting group title	P-3074 + Finasteride Placebo
Reporting group description: Subjects received topical application of P-3074 contained finasteride 0.25% in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.	
Reporting group title	P-3074 Vehicle + Finasteride Placebo
Reporting group description: Subjects received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.	
Reporting group title	Oral Finasteride + P-3074 Vehicle
Reporting group description: Subjects received finasteride 1 mg tablet orally once daily followed by topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for the 24 weeks.	

Reporting group values	P-3074 + Finasteride Placebo	P-3074 Vehicle + Finasteride Placebo	Oral Finasteride + P- 3074 Vehicle
Number of subjects	189	184	85
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	31.7 ± 5.4	32.0 ± 4.8	31.9 ± 5.6
Gender categorical Units: Subjects			
Male	189	184	85
Race Units: Subjects			
Asian	2	1	0
Black/African American	0	0	1
Caucasian/White	187	181	83
Other	0	2	1

Reporting group values	Total		
Number of subjects	458		
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	-		
Gender categorical Units: Subjects			
Male	458		

Race			
Units: Subjects			
Asian	3		
Black/African American	1		
Caucasian/White	451		
Other	3		

## End points

### End points reporting groups

Reporting group title	P-3074 + Finasteride Placebo
Reporting group description: Subjects received topical application of P-3074 contained finasteride 0.25% in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.	
Reporting group title	P-3074 Vehicle + Finasteride Placebo
Reporting group description: Subjects received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.	
Reporting group title	Oral Finasteride + P-3074 Vehicle
Reporting group description: Subjects received finasteride 1 mg tablet orally once daily followed by topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for the 24 weeks.	

### Primary: Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24

End point title	Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24
End point description: The change from baseline in the TAHC within a 1 cm <sup>2</sup> (square centimeter) of baldness area at Week 24, were assessed by macro photographic techniques analysis. The Investigator selected a target area in the anterior leading edge of the vertex thinning area. A small dot tattoo was placed in the center of the circle of the clipped hairs. Using the tattoo as a reference point, the circular area was photographed and a 1 cm <sup>2</sup> circular area within the target area was analysed. Change is the adjusted mean of Week 24 minus baseline. The data provided here is for Intent-to-Treat (ITT) Population included all subjects who had measurements both at baseline and on treatment: i.e. subjects who had measurements in regards to hair count both at baseline and on treatment. The analysis uses a covariance pattern model adjusted for treatment group, center, visit and treatment-by-visit interaction as fixed effects and baseline hair count as a covariate with an unstructured covariance structure.	
End point type	Primary
End point timeframe: Baseline and Week 24	

End point values	P-3074 + Finasteride Placebo	P-3074 Vehicle + Finasteride Placebo	Oral Finasteride + P-3074 Vehicle	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	105	97	48	
Units: hairs				
arithmetic mean (standard deviation)	20.2 (± 2.88)	6.7 (± 3.01)	21.1 (± 3.90)	

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo



Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	13.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.8
upper limit	21.3
Variability estimate	Standard error of the mean
Dispersion value	3.94

### Secondary: Adjusted Mean Change From Baseline in Hair Growth Assessed by TAHC in the Vertex at Week 12

End point title	Adjusted Mean Change From Baseline in Hair Growth Assessed by TAHC in the Vertex at Week 12
-----------------	---

#### End point description:

The change from baseline in the TAHC within a 1 cm<sup>2</sup> of baldness area at Week 12, were assessed by macro photographic techniques analysis. The Investigator selected a target area in the anterior leading edge of the vertex thinning area. A small dot tattoo was placed in the center of the circle of the clipped hairs. Using the tattoo as a reference point, the circular area was photographed and a 1 cm<sup>2</sup> circular area within the target area was analysed. Change is the adjusted mean of Week 24 minus baseline. The data provided here is for ITT Population included all subjects who had measurements both at baseline and on treatment: i.e. subjects who had measurements in regards to hair count both at baseline and on treatment. The analysis uses a covariance pattern model adjusted for treatment group, center, visit and treatment-by-visit interaction as fixed effects and baseline hair count as a covariate with an unstructured covariance structure.

End point type	Secondary
----------------	-----------

#### End point timeframe:

Baseline and Week 12

End point values	P-3074 + Finasteride Placebo	P-3074 Vehicle + Finasteride Placebo	Oral Finasteride + P-3074 Vehicle	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	105	97	48	
Units: hairs				
arithmetic mean (standard deviation)	20.4 (± 2.41)	7.6 (± 2.46)	22.5 (± 3.31)	

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo

Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	12.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.5
upper limit	19.5
Variability estimate	Standard error of the mean
Dispersion value	3.19

### Secondary: Adjusted Mean Change From Baseline in Target Area Hair Width (TAHW) in the Vertex at Weeks 12 and 24

End point title	Adjusted Mean Change From Baseline in Target Area Hair Width (TAHW) in the Vertex at Weeks 12 and 24
-----------------	--

#### End point description:

The change from baseline in the TAHW within a 1 cm<sup>2</sup> of baldness area at Weeks 12 and 24, were assessed by macro photographic techniques analysis. The Investigator selected a target area in the anterior leading edge of the vertex thinning area. A small dot tattoo was placed in the center of the circle of the clipped hairs. Using the tattoo as a reference point, the circular area was photographed and a 1 cm<sup>2</sup> circular area within the target area was analysed. Change is the adjusted mean of Weeks 12 and 24 minus baseline, respectively. The data provided here is for ITT Population included all subjects who had measurements both at baseline and on treatment: i.e. subjects who had measurements in regards to hair count both at baseline and on treatment. The analysis uses a covariance pattern model adjusted for treatment group, center, visit and treatment-by-visit interaction as fixed effects and baseline hair count as a covariate with an unstructured covariance structure.

End point type	Secondary
----------------	-----------

#### End point timeframe:

Baseline, Week 12 and Week 24

End point values	P-3074 + Finasteride Placebo	P-3074 Vehicle + Finasteride Placebo	Oral Finasteride + P-3074 Vehicle	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	105	97	48	
Units: micrometer				
arithmetic mean (standard deviation)				
Week 12	-1.1231 (± 0.30653)	-0.7207 (± 0.31033)	-0.6938 (± 0.41951)	
Week 24	-0.8052 (± 0.35151)	-1.5289 (± 0.36691)	0.7163 (± 0.46679)	

### Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description:	
Statistical Analysis details presented here is for Week 12	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.322
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.4024
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.202
upper limit	0.3971
Variability estimate	Standard error of the mean
Dispersion value	0.4057

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
Statistical Analysis details presented here is for Week 24	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.131
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	0.7237
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2184
upper limit	1.6657
Variability estimate	Standard error of the mean
Dispersion value	0.47799

### **Secondary: Adjusted Mean Overall Male Hair Growth Questionnaire (MHGQ) Score as Assessed by the Subject at Weeks 12 and 24**

End point title	Adjusted Mean Overall Male Hair Growth Questionnaire (MHGQ) Score as Assessed by the Subject at Weeks 12 and 24
-----------------	---

End point description:

Subjects assessed their scalp hair using a validated, self-administered MHGQ, which was given in their language. The self-administered MHGQ overall score assessed using the following 5-point scale: 1 = very satisfied, 2 = satisfied, 3 = neutral (neither satisfied nor dissatisfied), 4 = dissatisfied, 5 = very

dissatisfied. A higher score indicated a worse outcome. The questionnaire was administered to eligible subjects to subjectively measure their perception of hair growth. A higher score indicated a worse outcome. The data provided here is for ITT Population included all subjects who had measurements both at baseline and on treatment: i.e. subjects who had measurements in regards to hair count both at baseline and on treatment. The analysis uses a covariance pattern model adjusted for treatment group, center, visit and treatment-by-visit interaction as fixed effects and baseline hair count as a covariate with an unstructured covariance structure.

End point type	Secondary
End point timeframe:	
Baseline, Week 12 and Week 24	

End point values	P-3074 + Finasteride Placebo	P-3074 Vehicle + Finasteride Placebo	Oral Finasteride + P-3074 Vehicle	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	105	97	48	
Units: score on a scale				
arithmetic mean (standard error)				
Week 12	2.9 (± 0.08)	3.0 (± 0.09)	2.8 (± 0.12)	
Week 24	2.8 (± 0.09)	3.0 (± 0.10)	2.9 (± 0.13)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Statistical Analysis details presented here is for Week 12	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.569
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	0.2
Variability estimate	Standard error of the mean
Dispersion value	0.11

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Statistical Analysis details presented here is for Week 24	

Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.129
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	0.1
Variability estimate	Standard error of the mean
Dispersion value	0.12

### Secondary: Adjusted Mean Change From Baseline in Subject Hair Growth/Loss at Weeks 12 and 24, Assessed for the Vertex by Investigator

End point title	Adjusted Mean Change From Baseline in Subject Hair Growth/Loss at Weeks 12 and 24, Assessed for the Vertex by Investigator
-----------------	--

#### End point description:

The local Investigator assessed change in hair growth from Baseline to Week 12 and from Baseline to Week 24, using a 7-point scale. The evaluation was done by the Investigator or designee, by comparing the global vertex view photograph obtained at baseline visit with the subjects actual scalp at 12 and 24 weeks. For the purpose of assessment of changes in hair growth by Investigators screening visits (where global photos were taken) were used as Baseline. The change from Baseline in hair growth was assessed using the following 7-point scale: -3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased. The data provided here is for ITT Population. The analysis uses a covariance pattern model adjusted for treatment group, center, visit and treatment-by-visit interaction as fixed effects with an unstructured covariance structure.

End point type	Secondary
----------------	-----------

#### End point timeframe:

Baseline, Week 12 and Week 24

End point values	P-3074 + Finasteride Placebo	P-3074 Vehicle + Finasteride Placebo	Oral Finasteride + P-3074 Vehicle	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	105	97	48	
Units: score on a scale				
arithmetic mean (standard error)				
Week 12	0.5 (± 0.10)	0.4 (± 0.11)	0.5 (± 0.15)	
Week 24	0.8 (± 0.09)	0.3 (± 0.09)	0.7 (± 12)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Statistical Analysis details presented here is for Week 12	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.708
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.3
Variability estimate	Standard error of the mean
Dispersion value	0.14

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Statistical Analysis details presented here is for Week 24	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2
upper limit	0.7
Variability estimate	Standard error of the mean
Dispersion value	0.12

## Secondary: Adjusted Mean Change From Baseline in Subject Hair Growth/Loss at Weeks 12 and 24, Assessed for the Vertex by Blind Assessor

End point title	Adjusted Mean Change From Baseline in Subject Hair Growth/Loss at Weeks 12 and 24, Assessed for the Vertex by Blind Assessor
-----------------	--

**End point description:**

An independent blinded assessor was responsible for evaluating, under blinded conditions, the screening global photographs of the target area for all subjects. They evaluated the eligibility of each subjects according to the clinical inclusion criteria. The independent blinded assessor assessed the change of the hair growth from Baseline to Week 12 and from Baseline to Week 24, using a 7-point scale: -3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased. This assessment was performed by comparing the global photographs obtained at screening visit with those subsequently obtained at Weeks 12 and 24. The data provided here is for ITT. The analysis uses a covariance pattern model adjusted for treatment group, center, visit and treatment-by-visit interaction as fixed effects with an unstructured covariance structure.

End point type	Secondary
End point timeframe:	
Baseline, Week 12 and Week 24	

End point values	P-3074 + Finasteride Placebo	P-3074 Vehicle + Finasteride Placebo	Oral Finasteride + P-3074 Vehicle	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	105	97	48	
Units: score on a scale				
arithmetic mean (standard error)				
Week 12	0.0 (± 0.08)	0.2 (± 0.08)	0.2 (± 0.11)	
Week 24	0.2 (± 0.09)	0.1 (± 0.09)	0.3 (± 0.12)	

**Statistical analyses**

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Statistical Analysis details presented here is for Week 12	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.179
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	0.1
Variability estimate	Standard error of the mean
Dispersion value	0.1

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
Statistical Analysis details presented here is for Week 24	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.262
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	0.4
Variability estimate	Standard error of the mean
Dispersion value	0.12

### Secondary: Adjusted Mean International Index of Erectile Function (IIEF-2) Scores at Weeks 4, 8, 12 and 24

End point title	Adjusted Mean International Index of Erectile Function (IIEF-2) Scores at Weeks 4, 8, 12 and 24
End point description:	
<p>The 15-question IIEF-2 Questionnaire (Sexual Function Questionnaire) was used to evaluate any changes in sexual function and activity, at Weeks 4, 8, 12 and 24. A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. Erectile function domain has 6 questions with maximum score for domain is 30. Orgasmic function domain has 2 questions with maximum score for domain is 10. , Sexual desire function domain has 2 questions with maximum score for domain is 10. Intercourse satisfaction function domain has 3 questions with maximum score for domain is 15. Overall Satisfaction domain has 2 questions with maximum score for domain is 10. A higher score indicated a worse outcome in that domain.</p>	
End point type	Secondary
End point timeframe:	
Weeks 4, 8, 12 and 24	

End point values	P-3074 + Finasteride Placebo	P-3074 Vehicle + Finasteride Placebo	Oral Finasteride + P-3074 Vehicle	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	105	97	48	
Units: score on a scale				
arithmetic mean (standard error)				
Erectile Function Score, Week 4	24.5 (± 0.76)	26.2 (± 0.79)	23.5 (± 1.08)	
Erectile Function Score, Week 8	24.3 (± 0.80)	24.9 (± 0.83)	24.4 (± 1.15)	
Erectile Function Score, Week 12	25.3 (± 0.73)	25.5 (± 0.77)	23.6 (± 1.04)	
Erectile Function Score, Week 24	25.3 (± 0.74)	26.1 (± 0.79)	24.9 (± 1.05)	



Orgasmic Function Score, Week 4	9.3 (± 0.21)	9.0 (± 0.22)	8.9 (± 0.30)	
Orgasmic Function Score, Week 8	8.7 (± 0.26)	8.7 (± 0.27)	9.1 (± 0.38)	
Orgasmic Function Score, Week 12	9.4 (± 0.21)	8.9 (± 0.22)	9.0 (± 0.30)	
Orgasmic Function Score, Week 24	8.9 (± 0.25)	9.1 (± 0.26)	9.0 (± 0.35)	
Sexual Desire Score, Week 4	7.3 (± 0.17)	7.5 (± 0.17)	7.1 (± 0.24)	
Sexual Desire Score, Week 8	7.4 (± 0.16)	7.4 (± 0.17)	7.6 (± 0.23)	
Sexual Desire Score, Week 12	7.7 (± 0.15)	8.0 (± 0.16)	7.8 (± 0.21)	
Sexual Desire Score, Week 24	7.7 (± 0.17)	7.7 (± 0.18)	7.8 (± 0.24)	
Intercourse Satisfaction Score, Week 4	9.4 (± 0.49)	10.7 (± 0.51)	8.5 (± 0.69)	
Intercourse Satisfaction Score, Week 8	9.6 (± 0.49)	9.9 (± 0.51)	9.0 (± 0.70)	
Intercourse Satisfaction Score, Week 12	9.9 (± 0.49)	10.2 (± 0.51)	8.3 (± 0.69)	
Intercourse Satisfaction Score, Week 24	9.8 (± 0.47)	10.8 (± 0.50)	8.9 (± 0.67)	
Overall Satisfaction Score, Week 4	7.9 (± 0.22)	8.0 (± 0.22)	7.9 (± 0.31)	
Overall Satisfaction Score, Week 8	7.9 (± 0.21)	7.8 (± 0.22)	7.8 (± 0.31)	
Overall Satisfaction Score, Week 12	8.1 (± 0.22)	8.1 (± 0.23)	7.6 (± 0.31)	
Overall Satisfaction Score, Week 24	8.0 (± 0.22)	8.1 (± 0.23)	8.2 (± 0.31)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Statistical Analysis details presented here is for Erectile Function Score, Week 4	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.103
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.7
upper limit	0.3
Variability estimate	Standard error of the mean
Dispersion value	1.03

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Statistical Analysis details presented here is for Erectile Function Score, Week 8	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo

Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.545
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	1.5
Variability estimate	Standard error of the mean
Dispersion value	1.1

<b>Statistical analysis title</b>	Statistical Analysis 3
Statistical analysis description:	
Statistical Analysis details presented here is for Erectile Function Score, Week 12	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.842
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	1.8
Variability estimate	Standard error of the mean
Dispersion value	1

<b>Statistical analysis title</b>	Statistical Analysis 4
Statistical analysis description:	
Statistical Analysis details presented here is for Erectile Function Score, Week 24	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.449
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	1.2
Variability estimate	Standard error of the mean
Dispersion value	1.02

<b>Statistical analysis title</b>	Statistical Analysis 5
Statistical analysis description:	
Statistical Analysis details presented here is for Orgasmic Function Score, Week 4	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.272
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.9
Variability estimate	Standard error of the mean
Dispersion value	0.28

<b>Statistical analysis title</b>	Statistical Analysis 6
Statistical analysis description:	
Statistical Analysis details presented here is for Orgasmic Function Score, Week 8	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.918
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	0.8
Variability estimate	Standard error of the mean
Dispersion value	0.36

<b>Statistical analysis title</b>	Statistical Analysis 7
Statistical analysis description:	
Statistical Analysis details presented here is for Orgasmic Function Score, Week 12	
Comparison groups	P-3074 Vehicle + Finasteride Placebo v P-3074 + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.078
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	1.1
Variability estimate	Standard error of the mean
Dispersion value	0.078

<b>Statistical analysis title</b>	Statistical Analysis 8
Statistical analysis description:	
Statistical Analysis details presented here is for Orgasmic Function Score, Week 24	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.593
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	0.5
Variability estimate	Standard error of the mean
Dispersion value	0.34

<b>Statistical analysis title</b>	Statistical Analysis 9
Statistical analysis description:	
Statistical Analysis details presented here is for Sexual Desire Score, Week 4	

Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.295
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	0.2
Variability estimate	Standard error of the mean
Dispersion value	0.23

<b>Statistical analysis title</b>	Statistical Analysis 10
Statistical analysis description:	
Statistical Analysis details presented here is for Sexual Desire Score, Week 8	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.926
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	0.4
Variability estimate	Standard error of the mean
Dispersion value	0.22

<b>Statistical analysis title</b>	Statistical Analysis 11
Statistical analysis description:	
Statistical Analysis details presented here is for Sexual Desire Score, Week 12	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo

Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.183
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	0.1
Variability estimate	Standard error of the mean
Dispersion value	0.2

<b>Statistical analysis title</b>	Statistical Analysis 12
Statistical analysis description:	
Statistical Analysis details presented here is for Sexual Desire Score, Week 24	
Comparison groups	P-3074 Vehicle + Finasteride Placebo v P-3074 + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.981
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	0.5
Variability estimate	Standard error of the mean
Dispersion value	0.23

<b>Statistical analysis title</b>	Statistical Analysis 13
Statistical analysis description:	
Statistical Analysis details presented here is for Intercourse Satisfaction Score, Week 4	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.041
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-1.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	-0.1
Variability estimate	Standard error of the mean
Dispersion value	0.66

<b>Statistical analysis title</b>	Statistical Analysis 14
Statistical analysis description:	
Statistical Analysis details presented here is for Intercourse Satisfaction Score, Week 8	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.562
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	0.9
Variability estimate	Standard error of the mean
Dispersion value	0.67

<b>Statistical analysis title</b>	Statistical Analysis 15
Statistical analysis description:	
Statistical Analysis details presented here is for Intercourse Satisfaction Score, Week 12	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.642
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	1
Variability estimate	Standard error of the mean
Dispersion value	0.66

<b>Statistical analysis title</b>	Statistical Analysis 16
Statistical analysis description:	
Statistical Analysis details presented here is for Intercourse Satisfaction Score, Week 24	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.156
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	0.4
Variability estimate	Standard error of the mean
Dispersion value	0.65

<b>Statistical analysis title</b>	Statistical Analysis 17
Statistical analysis description:	
Statistical Analysis details presented here is for Overall Satisfaction Score, Week 4	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.824
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.6
upper limit	0.5
Variability estimate	Standard error of the mean
Dispersion value	0.29

<b>Statistical analysis title</b>	Statistical Analysis 18
Statistical analysis description:	
Statistical Analysis details presented here is for Overall Satisfaction Score, Week 8	



Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.713
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	0.7
Variability estimate	Standard error of the mean
Dispersion value	0.29

<b>Statistical analysis title</b>	Statistical Analysis 19
Statistical analysis description:	
Statistical Analysis details presented here is for Overall Satisfaction Score, Week 12	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.993
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.6
upper limit	0.6
Variability estimate	Standard error of the mean
Dispersion value	0.3

<b>Statistical analysis title</b>	Statistical Analysis 20
Statistical analysis description:	
Statistical Analysis details presented here is for Overall Satisfaction Score, Week 24	
Comparison groups	P-3074 + Finasteride Placebo v P-3074 Vehicle + Finasteride Placebo

Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.55
Method	Mixed linear model
Parameter estimate	LS Mean Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	0.4
Variability estimate	Standard error of the mean
Dispersion value	0.3

### Secondary: Local Tolerability as Assessed by Incidence Rate of Skin Irritation Event Via Severity Score for Skin Irritation Scale

End point title	Local Tolerability as Assessed by Incidence Rate of Skin Irritation Event Via Severity Score for Skin Irritation Scale
End point description:	
Local tolerability at the application site was assessed to rate the severity of any skin irritation. The Investigator used the Severity score for skin Irritation scale to assess local tolerability. The dermal response and other effects indicative irritation responses were recorded at time of examination. Anything other than "No evidence of irritation" under Dermal Response was considered as a Dermal Response Skin Irritation event. Anything other than "No other effects" under Other Effects was considered as an Other Effects of Skin Irritation event. The event incidence rate is calculated as the number of events interest divided by total personal time in years. Safety Population includes all randomized subjects who received at least one application of the IMP.	
End point type	Secondary
End point timeframe:	
Baseline to Week 24	

End point values	P-3074 + Finasteride Placebo	P-3074 Vehicle + Finasteride Placebo	Oral Finasteride + P-3074 Vehicle	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	181	181	84	
Units: Events per personal years				
number (not applicable)				
Dermal Response	0.340	0.245	0.661	
Other Effects	0.368	0.463	0.755	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs)

---

**and Serious TEAEs**

---

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
-----------------	---

---

End point description:

An Adverse event is defined as any untoward medical occurrence in a subjects or clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with treatment. A serious AE was an AE that results in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect and medically significant event. The Treatment Emergent Adverse Events (TEAEs) is defined as all AEs occurring on or after the first dose of the IMP. Safety Population includes all randomized subjects who received at least one application of the IMP.

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

From the start of IMP upto 28 weeks

---

End point values	P-3074 + Finasteride Placebo	P-3074 Vehicle + Finasteride Placebo	Oral Finasteride + P-3074 Vehicle	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	181	181	84	
Units: Subjects				
number (not applicable)				
TEAEs	75	76	41	
Serious TEAEs	4	5	1	

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From the start of the IMP up to 28 weeks

Adverse event reporting additional description:

The data presented is for the safety population which includes all randomized subjects who received at least one application of the investigational medicinal product.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

### Reporting groups

Reporting group title	P-3074 + Finasteride Placebo
-----------------------	------------------------------

Reporting group description:

Subjects received topical application of P-3074 contained finasteride 0.25% in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.

Reporting group title	P-3074 Vehicle + Finasteride Placebo
-----------------------	--------------------------------------

Reporting group description:

Subjects received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.

Reporting group title	Oral Finasteride + P-3074 Vehicle
-----------------------	-----------------------------------

Reporting group description:

Subjects received finasteride 1 mg tablet orally once daily followed by topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for the 24 weeks.

Serious adverse events	P-3074 + Finasteride Placebo	P-3074 Vehicle + Finasteride Placebo	Oral Finasteride + P- 3074 Vehicle
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 181 (2.21%)	5 / 181 (2.76%)	1 / 84 (1.19%)
number of deaths (all causes)	6	5	1
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Exposure via father			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fractured base			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Haematoma			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal septum deviation			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax spontaneous			

subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Tendonitis			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	<b>P-3074 + Finasteride Placebo</b>	<b>P-3074 Vehicle + Finasteride Placebo</b>	<b>Oral Finasteride + P- 3074 Vehicle</b>
Total subjects affected by non-serious adverse events			
subjects affected / exposed	74 / 181 (40.88%)	73 / 181 (40.33%)	40 / 84 (47.62%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Application site pain			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Application site pruritus			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Chest discomfort			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Face oedema			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1

Influenza like illness subjects affected / exposed occurrences (all)	0 / 181 (0.00%) 0	1 / 181 (0.55%) 1	0 / 84 (0.00%) 0
Non-cardiac chest pain subjects affected / exposed occurrences (all)	0 / 181 (0.00%) 0	1 / 181 (0.55%) 1	0 / 84 (0.00%) 0
Peripheral swelling subjects affected / exposed occurrences (all)	1 / 181 (0.55%) 1	0 / 181 (0.00%) 0	0 / 84 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	3 / 181 (1.66%) 4	1 / 181 (0.55%) 2	1 / 84 (1.19%) 1
Thirst subjects affected / exposed occurrences (all)	0 / 181 (0.00%) 0	1 / 181 (0.55%) 1	0 / 84 (0.00%) 0
Immune system disorders Dust allergy subjects affected / exposed occurrences (all)	0 / 181 (0.00%) 0	0 / 181 (0.00%) 0	1 / 84 (1.19%) 1
Social circumstances High risk sexual behaviour subjects affected / exposed occurrences (all)	0 / 181 (0.00%) 0	1 / 181 (0.55%) 1	0 / 84 (0.00%) 0
Stress at work subjects affected / exposed occurrences (all)	1 / 181 (0.55%) 1	0 / 181 (0.00%) 0	0 / 84 (0.00%) 0
Reproductive system and breast disorders Balanoposthitis subjects affected / exposed occurrences (all)	0 / 181 (0.00%) 0	0 / 181 (0.00%) 0	1 / 84 (1.19%) 1
Erectile dysfunction subjects affected / exposed occurrences (all)	2 / 181 (1.10%) 2	2 / 181 (1.10%) 2	2 / 84 (2.38%) 2
Sexual dysfunction subjects affected / exposed occurrences (all)	2 / 181 (1.10%) 2	0 / 181 (0.00%) 0	0 / 84 (0.00%) 0

Respiratory, thoracic and mediastinal disorders			
Catarrh			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Cough			
subjects affected / exposed	1 / 181 (0.55%)	2 / 181 (1.10%)	0 / 84 (0.00%)
occurrences (all)	1	2	0
Dyspnoea			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	1 / 181 (0.55%)	7 / 181 (3.87%)	3 / 84 (3.57%)
occurrences (all)	1	7	3
Nasal pruritus			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Rhinitis allergic			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Rhinorrhoea			
subjects affected / exposed	2 / 181 (1.10%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	2	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	1 / 84 (1.19%)
occurrences (all)	0	1	2
Burnout syndrome			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Depression			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	1 / 84 (1.19%)
occurrences (all)	0	1	1
Initial insomnia			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Insomnia			



subjects affected / exposed	1 / 181 (0.55%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	1	1	0
Libido decreased			
subjects affected / exposed	1 / 181 (0.55%)	3 / 181 (1.66%)	1 / 84 (1.19%)
occurrences (all)	1	3	1
Loss of libido			
subjects affected / exposed	0 / 181 (0.00%)	2 / 181 (1.10%)	3 / 84 (3.57%)
occurrences (all)	0	2	3
Stress			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	1 / 84 (1.19%)
occurrences (all)	0	1	1
Blood bilirubin increased			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	2	0	0
Blood bilirubin unconjugated increased			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Blood glucose increased			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Blood pressure systolic increased			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Blood uric acid increased			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Crystal urine present			

subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	1	0	1
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	2 / 84 (2.38%)
occurrences (all)	0	0	2
Liver function test increased			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Protein urine present			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Red blood cells urine positive			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Stress echocardiogram abnormal			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Transaminases increased			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Weight increased			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
White blood cells urine positive			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Arthropod bite			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Contusion			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Fall			

subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Foot fracture			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Injury			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Joint dislocation			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Laceration			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Ligament rupture			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Meniscus injury			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Skin abrasion			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Skin injury			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Upper limb fracture			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Sinus arrhythmia			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Tachycardia			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0

Nervous system disorders			
Carpal tunnel syndrome			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Cervicogenic headache			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Dizziness			
subjects affected / exposed	1 / 181 (0.55%)	2 / 181 (1.10%)	0 / 84 (0.00%)
occurrences (all)	1	4	0
Head discomfort			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Hyperaesthesia			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Paraesthesia			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Presyncope			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Sciatica			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Somnolence			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Syncope			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Headache			
subjects affected / exposed	17 / 181 (9.39%)	20 / 181 (11.05%)	8 / 84 (9.52%)
occurrences (all)	25	29	9
Blood and lymphatic system disorders			

Lymphadenopathy subjects affected / exposed occurrences (all)	1 / 181 (0.55%) 1	0 / 181 (0.00%) 0	1 / 84 (1.19%) 1
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)	1 / 181 (0.55%) 1	1 / 181 (0.55%) 1	0 / 84 (0.00%) 0
Eye disorders Blepharitis subjects affected / exposed occurrences (all)	1 / 181 (0.55%) 1	0 / 181 (0.00%) 0	0 / 84 (0.00%) 0
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	1 / 181 (0.55%) 1	1 / 181 (0.55%) 1	0 / 84 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 181 (0.55%) 1	0 / 181 (0.00%) 0	1 / 84 (1.19%) 1
Anal pruritus subjects affected / exposed occurrences (all)	1 / 181 (0.55%) 1	0 / 181 (0.00%) 0	0 / 84 (0.00%) 0
Crohn's disease subjects affected / exposed occurrences (all)	0 / 181 (0.00%) 0	1 / 181 (0.55%) 1	0 / 84 (0.00%) 0
Dental caries subjects affected / exposed occurrences (all)	0 / 181 (0.00%) 0	1 / 181 (0.55%) 1	0 / 84 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	2 / 181 (1.10%) 2	2 / 181 (1.10%) 2	2 / 84 (2.38%) 2
Dyspepsia subjects affected / exposed occurrences (all)	0 / 181 (0.00%) 0	2 / 181 (1.10%) 3	1 / 84 (1.19%) 2
Dysphagia subjects affected / exposed occurrences (all)	1 / 181 (0.55%) 1	0 / 181 (0.00%) 0	0 / 84 (0.00%) 0
Food poisoning			

subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Gastritis			
subjects affected / exposed	2 / 181 (1.10%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	2	1	0
Inguinal hernia perforation			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	0 / 181 (0.00%)	3 / 181 (1.66%)	0 / 84 (0.00%)
occurrences (all)	0	3	0
Odynophagia			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Stomatitis			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Toothache			
subjects affected / exposed	3 / 181 (1.66%)	3 / 181 (1.66%)	2 / 84 (2.38%)
occurrences (all)	3	3	3
Vomiting			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Hepatobiliary disorders			
Hepatocellular injury			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Hypertransaminasaemia			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Dermal cyst			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Diffuse alopecia			

subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Erythema			
subjects affected / exposed	4 / 181 (2.21%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	5	0	0
Eczema			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Papule			
subjects affected / exposed	1 / 181 (0.55%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	3	2	0
Pruritus			
subjects affected / exposed	5 / 181 (2.76%)	1 / 181 (0.55%)	1 / 84 (1.19%)
occurrences (all)	5	3	1
Pruritus generalised			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Rash			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Rash papular			
subjects affected / exposed	2 / 181 (1.10%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	2	0	0
Rash pruritic			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Rash vesicular			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Sebaceous gland disorder			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 181 (0.00%)	2 / 181 (1.10%)	0 / 84 (0.00%)
occurrences (all)	0	2	0
Skin burning sensation			

subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Skin irritation			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Skin plaque			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Urticaria			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Vitiligo			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Proteinuria			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Back pain			
subjects affected / exposed	2 / 181 (1.10%)	5 / 181 (2.76%)	1 / 84 (1.19%)
occurrences (all)	2	6	1
Bone pain			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Bursitis			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Muscle tightness			



subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Musculoskeletal stiffness			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			
subjects affected / exposed	1 / 181 (0.55%)	2 / 181 (1.10%)	0 / 84 (0.00%)
occurrences (all)	1	2	0
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Anorectal infection			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Bronchitis			
subjects affected / exposed	1 / 181 (0.55%)	2 / 181 (1.10%)	0 / 84 (0.00%)
occurrences (all)	1	2	0
Conjunctivitis			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Epididymitis			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Gastritis helminthic			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis			
subjects affected / exposed	2 / 181 (1.10%)	4 / 181 (2.21%)	1 / 84 (1.19%)
occurrences (all)	2	4	1

Gastrointestinal infection			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	1	0	1
Herpes simplex			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Hordeolum			
subjects affected / exposed	0 / 181 (0.00%)	2 / 181 (1.10%)	0 / 84 (0.00%)
occurrences (all)	0	2	0
Infected bite			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	4 / 181 (2.21%)	2 / 181 (1.10%)	1 / 84 (1.19%)
occurrences (all)	4	2	1
Laryngitis			
subjects affected / exposed	1 / 181 (0.55%)	1 / 181 (0.55%)	1 / 84 (1.19%)
occurrences (all)	1	1	1
Nasopharyngitis			
subjects affected / exposed	28 / 181 (15.47%)	24 / 181 (13.26%)	15 / 84 (17.86%)
occurrences (all)	32	29	22
Oral herpes			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	1 / 84 (1.19%)
occurrences (all)	0	1	1
Otitis externa			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Otitis media acute			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Periodontitis			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Pertussis			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0

Pharyngitis			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Pulpitis dental			
subjects affected / exposed	1 / 181 (0.55%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	1	1	0
Rash pustular			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	2	0	0
Respiratory tract infection			
subjects affected / exposed	1 / 181 (0.55%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	1	1	0
Respiratory tract infection viral			
subjects affected / exposed	3 / 181 (1.66%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	3	0	0
Rhinitis			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Sinusitis			
subjects affected / exposed	1 / 181 (0.55%)	2 / 181 (1.10%)	1 / 84 (1.19%)
occurrences (all)	1	2	1
Testicular abscess			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Tonsillitis			
subjects affected / exposed	0 / 181 (0.00%)	3 / 181 (1.66%)	0 / 84 (0.00%)
occurrences (all)	0	4	0
Tooth infection			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			
subjects affected / exposed	2 / 181 (1.10%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	3	1	0
Viral infection			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0

Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 181 (0.55%)	0 / 181 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 181 (0.00%)	0 / 181 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Hypophosphataemia *			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Vitamin B12 deficiency			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Vitamin D deficiency			
subjects affected / exposed	0 / 181 (0.00%)	1 / 181 (0.55%)	0 / 84 (0.00%)
occurrences (all)	0	1	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported